The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by The Rogosin Institute
Sponsor:
Information provided by (Responsible Party):
The Rogosin Institute
ClinicalTrials.gov Identifier:
NCT01109368
First received: April 21, 2010
Last updated: May 22, 2014
Last verified: May 2014

April 21, 2010
May 22, 2014
June 2010
May 2020   (final data collection date for primary outcome measure)
Change in disease progression [ Time Frame: 10 years ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT01109368 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository

This repository will establish for the first time a system to carefully assess and monitor over time the general health and the amount of cholesterol in the arteries of U.S. children and adults with homozygous familial hypercholesterolemia (hoFH). Patients with this very rare disorder have very high blood levels of cholesterol from birth due to the inheritance of an abnormal gene from each parent. As a result, if untreated, heart attacks and sudden death occur in childhood. Treatments such as LDL-apheresis and liver transplant will lower the cholesterol level, but the best treatment and the best way to monitor the effect of the treatment on the arteries are unknown. The collection of clinical data and blood for analysis of known and yet-to-be discovered markers and predictors of arterial disease will yield new information about the natural history of the disorder and response to treatment. The repository will greatly aid the development of specific protocols that seek to learn more about this disease and new therapies.

Detailed information of "standard of care" procedures will be compiled in a database. These include medical history and physical exam, lipid profiles and other standard blood tests, dietary evaluation and counseling, cardiology evaluation including EKG and echocardiogram,ultrasound of carotids and femoral arteries, CT angiogram and, if indicated, intracoronary angiography (ICA) with intravascular ultrasound (IVUS) and stress echo or nuclear stress testing.

The recommendation for treatment will be individualized. Current options are a) FDA approved cholesterol-lowering medications: statins, ezetimibe b) LDL-apheresis c) liver transplant d) portacaval shunt e) investigational drugs. Treatment of vascular and/or valvular disease may include aspirin, beta blockers, clopidogrel, angioplasty with metal stent, coronary artery bypass surgery, aortic valve repair/replacement.

Research procedures will include medical photos of skin xanthomas, blood assays (apolipoproteins A and B, LDL particle size, homocysteine, TNF, IL-6, insulin, glucose, ICAM, VCAM, P and E selectin, and endothelial progenitor cells), and DNA analysis of the genes for the LDL receptor and other lipid-related genes.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Plasma, serum, monocytes

Non-Probability Sample

Males and females of any age with severely elevated LDL cholesterol levels without secondary causes and a family history consistent with an autosomal dominant disorder.

Homozygous Familial Hypercholesterolemia
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
May 2020
May 2020   (final data collection date for primary outcome measure)

Inclusion criteria:

1. Patients of any age and sex who meet clinical or genetic criteria for hoFH as follows:

  • Documented, untreated fasting LDL cholesterol level of > 500 mg/dL and triglycerides < 200 mg/dL on a cholesterol-lowering diet for at least 8 weeks with secondary causes excluded, AND:

    • DNA confirmation of a double mutation of the LDL receptor or apoB gene OR
    • LDL > 160 mg/dL in both biological parents not associated with a disorder know to elevate LDL OR
    • Coronary artery disease in one or both parents or grandparents < 55 years for males, < 65 for females OR
    • Tendinous/cutaneous xanthomas < age 10 or coronary artery disease < age 20

Exclusion criteria:

1. Inability of patient, or, if less than 18, a parent, to sign informed consent.

Both
Not Provided
No
Contact: Lisa C. Hudgins, M.D. 646-317-0805 lih2013@nyp.org
Contact: Chioma Okoro, MPH 212-249-8047 cno9001@nyp.org
United States
 
NCT01109368
0912010770
No
The Rogosin Institute
The Rogosin Institute
Not Provided
Principal Investigator: Lisa C. Hudgins, M.D. The Rogosin Institute
The Rogosin Institute
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP